With 4.23 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.74 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $43.71 whereas the lowest price it dropped to was $39.86. The 52-week range on IONS shows that it touched its highest point at $52.34 and its lowest point at $23.95 during that stretch. It currently has a 1-year price target of $56.62. Beta for the stock currently stands at 0.24.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IONS was up-trending over the past week, with a rise of 8.98%, but this was up by 27.79% over a month. Three-month performance surged to 59.90% while six-month performance rose 21.39%. The stock gained 24.69% in the past year, while it has lost -8.54% so far this year. A look at the trailing 12-month EPS for IONS yields -2.98 with Next year EPS estimates of -3.17. For the next quarter, that number is -0.23. This implies an EPS growth rate of -2.97% for this year and -1.15% for next year.
Float and Shares Shorts:
At present, 159.04 million IONS shares are outstanding with a float of 155.28 million shares on hand for trading. On 2025-06-13, short shares totaled 14.23 million, which was 893.9999 higher than short shares on 1747267200. In addition to Dr. Brett P. Monia Ph.D. as the firm’s Founder, CEO & Director, Ms. Elizabeth L. Hougen M.A., M.B.A., M.S. serves as its Executive VP of Finance & CFO.
Institutional Ownership:
Through their ownership of 1.0813099 of IONS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, IONS reported revenue of $131612000.0 and operating income of -$146947000.0. The EBITDA in the recently reported quarter was -$142506000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for IONS since 14 analysts follow the stock currently. There are 10 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With IONS analysts setting a high price target of 83.0 and a low target of 37.0, the average target price over the next 12 months is 57.88654. Based on these targets, IONS could surge 90.41% to reach the target high and fall by -15.12% to reach the target low. Reaching the average price target will result in a growth of 32.8% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.24118 being high and -$3.70565 being low. For IONS, this leads to a yearly average estimate of -$3.50371.
